Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 15

0 1 2 3 4 5
P=0.016
% Event -Free
60
40
20
0
100
80
Years from Randomization
HR=0.64 (95% CI: 0.44-0.93)
Neoadjuvant
NOAH
Event-Free Survival
L. Gianni et al, ASCO Annual Meeting 2013. Roche data on file.
HR=0.76 (95% CI: 0.67-0.86)
% Event -Free
60
40
20
0
0 2 4 6 8 10
P<0.0001
100
80
Years from Randomization
Adjuvant
HERA
Disease-Free Survival
Without T With T Without T With T
Trastuzumab Improves Outcomes in HER2+ EBC